American Heart Association Selects CV Therapeutics' Discovery of Role Of 'Good' Cholesterol-Regulating Gene as Top Ten 1999 Research Advances In Heart Disease

CVT and Incyte Demonstrate the Benefits of Genomics and Microarry Analysis

To Drug Discovery

Jan 03, 2000, 00:00 ET from CV Therapeutics, Inc. from ,Incyte Pharmaceuticals, Inc.

    PALO ALTO, Calif., Jan. 3 /PRNewswire/ --
 CV Therapeutics, Inc. (Nasdaq:   CVTX) and
 Incyte Pharmaceuticals, Inc. (Nasdaq:   INCY) announced that the American Heart
 Association has selected CV Therapeutics' discovery of the role of the "good"
 cholesterol-regulating gene, ABC1, as one of the top ten 1999 research
 advances in heart disease and stroke.  This discovery was presented at the
 American Heart Association's 72nd Scientific Sessions and published in the
 Journal of Clinical Investigation in 1999.
     Through the use of Incyte's gene expression microarray technology along
 with other techniques, scientists at CV Therapeutics, working with Incyte and
 University of Washington, identified that ABC1 is a key gene involved in the
 formation of high density lipoprotein (HDL), or "good" cholesterol.  Richard
 M. Lawn, Ph.D., Vice President, Discovery Research at CV Therapeutics and his
 colleagues at CVT then demonstrated that increasing levels of this gene in
 cultured cells in the laboratory enhances the removal of cholesterol from
 cultured cells.  These discoveries provided the first biological evidence
 suggesting that drug therapies that increase the level of ABC1 might aid in
 the removal of cholesterol from the body, holding the potential for reducing
 the risk of heart disease among the general population.
     According to the American Heart Association, the annual list was first
 created in 1996 to highlight the achievements in basic and clinical research
 that may have the greatest impact in improving the prevention and treatment of
 cardiovascular disease, the nation's number one killer.
     "The American Heart Association's recognition is testimony to the
 potential this finding holds for discovering new therapeutic solutions for HDL
 cholesterol management," said Louis G. Lange, M.D., Ph.D., Chairman and Chief
 Executive Officer of CV Therapeutics.  "This discovery demonstrates how
 combining cardiovascular expertise along with the power of genomics and
 microarray technology can lead to new drug discovery targets that could
 potentially help the many people suffering from cardiovascular diseases."
     This discovery also represented the first time gene expression microarray
 analysis has been used to identify a defect associated with a human genetic
 condition.  This technique uses a micro-chip with thousands of genes covering
 its surface. Microarray analysis dramatically reduces the amount of time
 usually necessary to monitor the expression level of thousands of genes
 concurrently.  Scientists were able to pinpoint the faulty gene and its
 encoded protein with the help of Incyte's Gene Album(TM) microarrays by
 studying the activity of 60,000 genes from people with Tangier disease, a rare
 genetic disorder that results in dangerously low levels of HDL, and an
 increased risk for heart attack, against genes from an unaffected individual.
     "This is a validation of the role of genomics in the understanding and
 treatment of disease," said Randy Scott, President and Chief Scientific
 Officer of Incyte Pharmaceuticals.  "We are appreciative of the
 acknowledgement by the American Heart Association and would welcome future
 collaboration opportunities with CV Therapeutics."
     The CV Therapeutics and Incyte collaboration is focused on creating gene
 expression profiles of cardiovascular disease models.  CV Therapeutics
 contributes its molecular cardiology expertise and Incyte contributes its
 genomics expertise to the collaboration.
     In addition to historical information, this press release contains
 forward-looking statements that involve risks and uncertainties, including,
 but not limited to, uncertainties related to CV Therapeutics' early stage of
 development and clinical trials. Actual results could differ materially.
 Factors that could cause or contribute to such differences are more fully
 discussed in CV Therapeutics' Prospectus dated October 6, 1999.
     Except for the historical information contained herein, the matters set
 forth in this press release, are forward-looking statements within the meaning
 of the "safe harbor" provisions of the Private Securities Litigation Reform
 Act of 1995.  These forward-looking statements are subject to risks and
 uncertainties that may cause actual results to differ materially.  For a
 discussion of factors that may cause results to differ, see Incyte's SEC
 reports, including its Annual Report on Form 10-Q for the quarter ended
 September 30, 1999.  Incyte disclaims any intent or obligation to update these
 forward-looking statements.
     CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a
 biopharmaceutical company focused on applying molecular cardiology to the
 discovery, development and commercialization of novel, small molecule drugs
 for the treatment of cardiovascular diseases. CVT currently has three drug
 candidates in clinical trials.  Ranolazine, the first in a new class of drugs
 known as partial fatty acid oxidation (pFOX) inhibitors for the potential
 treatment of angina, is in Phase III clinical trials.  CVT-510, for the
 potential treatment of atrial arrhythmias, is in Phase II clinical trials.  A
 third product, CVT-124, for the potential treatment of congestive heart
 failure (CHF), is in Phase II clinical trials.  For more information, please
 visit CV Therapeutics' web site at
     Incyte Pharmaceuticals, Inc. is a leading provider of an integrated
 platform of genomic technologies designed to aid in the understanding of the
 molecular basis of disease.  Incyte develops and markets genomic databases,
 genomic data management software, microarray-based gene expression services,
 related reagents and services.  These products and services assist
 pharmaceutical and biotechnology researchers with all phases of drug discovery
 and development including gene discovery, understanding disease pathways,
 identifying new disease targets and the discovery and correlation of gene
 sequence variation to disease.  For more information, visit Incyte's Web site

SOURCE CV Therapeutics, Inc.; Incyte Pharmaceuticals, Inc.